Solventum (NYSE:SOLV) Price Target Raised to $101.00

Solventum (NYSE:SOLV) had its price target boosted by Wedbush from $94.00 to $101.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have an outperform rating on the stock.

A number of other research firms have also recently issued reports on SOLV. Piper Sandler cut their price objective on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. BTIG Research upped their price target on Solventum from $91.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday. Mizuho set a $113.00 price target on Solventum in a report on Thursday. KeyCorp increased their price target on Solventum from $93.00 to $102.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, BMO Capital Markets started coverage on Solventum in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 price objective for the company. Seven investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $91.64.

Solventum Stock Up 0.0%

Shares of NYSE SOLV opened at $83.00 on Thursday. The firm has a market cap of $14.13 billion, a PE ratio of 10.15, a P/E/G ratio of 1.18 and a beta of 0.60. Solventum has a 12-month low of $62.38 and a 12-month high of $90.00. The company’s fifty day simple moving average is $79.40 and its 200 day simple moving average is $74.44. The company has a quick ratio of 0.75, a current ratio of 1.02 and a debt-to-equity ratio of 1.00.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.64. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The firm had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.15 billion. During the same period in the previous year, the firm posted $1.69 earnings per share. The business’s revenue was up 2.2% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, sell-side analysts forecast that Solventum will post 7.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SOLV. Independent Franchise Partners LLP increased its holdings in Solventum by 19.0% during the 4th quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock worth $1,216,785,000 after purchasing an additional 2,456,451 shares in the last quarter. Diamond Hill Capital Management LLC Investment Advisor bought a new position in shares of Solventum in the second quarter valued at approximately $150,066,000. Norges Bank bought a new position in shares of Solventum in the fourth quarter valued at approximately $147,467,000. Diamond Hill Capital Management Inc. boosted its position in shares of Solventum by 152.2% during the fourth quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company’s stock valued at $167,119,000 after buying an additional 1,272,921 shares during the last quarter. Finally, Boston Partners boosted its position in shares of Solventum by 26.1% during the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after buying an additional 959,543 shares during the last quarter.

More Solventum News

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Q2 results exceeded expectations. Solventum reported adjusted earnings of $2.55 per share versus the $1.91 consensus estimate, while revenue of $2.21 billion also topped forecasts. Organic sales increased 9.5%, and revenue grew 2.2% year over year. Solventum Stock Up as Q2 Earnings & Revenues Beat Estimates
• Positive Sentiment: Management raised 2026 earnings guidance to $7.10-$7.20 per share, above its previous outlook. Strong cash flow and the company’s share-repurchase activity further support investor sentiment, although some of the quarter’s benefit came from ERP implementation timing. Solventum outlines HIS separation and raises 2026 EPS guide
• Positive Sentiment: Analyst conviction strengthened. Piper Sandler raised its target to $105 and maintained an overweight rating; Wedbush lifted its target to $101 with an outperform rating; and Stifel increased its target to $100 with a buy rating. UBS also reiterated its buy recommendation. UBS Remains a Buy on Solventum Corporation
• Positive Sentiment: Software separation could sharpen the company’s focus. Solventum plans to separate its health information systems business, potentially creating a more focused medical-technology company and unlocking value from the remaining operations. Solventum to hive off healthcare software business

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.